
Icotrokinra
ICOTYDE is a once-daily pill for moderate to severe plaque psoriasis. Connect with a licensed dermatology provider to see if ICOTYDE is right for you.
Icotyde is an oral prescription medication used to treat moderate to severe plaque psoriasis in adults and adolescents who may need systemic therapy. Icotyde is typically considered when topical treatments alone aren’t enough.
Icotyde targets one of the key immune pathways behind psoriasis.
It works by blocking the IL-23 receptor, a signal in the immune system that drives inflammation and plaque formation.
By calming this overactive immune response, Icotyde helps:
Some people may experience mild side effects when starting Icotyde, including:
These are generally manageable and often improve over time.
Fill out a quick medical questionnaire and upload photos of your skin. In many cases, treatment can begin right away without a video consult.
If a visit is needed, you can book a quick video consult within 48 hours. Your provider takes the time to understand your skin and your goals.
Your provider creates a personalized plan, then your treatment is delivered to your door or sent to your local pharmacy.
Track your progress with photos and message your Care Team anytime for questions, refills, and guidance. We'll respond, 7 days a week.
ICOTYDE works by blocking the IL-23 receptor, a signal in the immune system that drives inflammation and plaque formation.
By calming this overactive immune response, Icotyde helps reduce inflammation, clear plaques, and improve overall skin appearance.



Your dermatology provider will review your skin and confirm whether ICOTYDE is the right fit before prescribing.

of patients achieved clear or almost clear skin (IGA 0/1) at Week 16 vs. 11% on placebo*
of patients achieved a 90% reduction in disease severity (PASI 90) at Week 16 vs. 4% on placebo*
of patients achieved clear or almost clear skin (IGA 0/1) by Week 24*
*Based on ICONIC-ADVANCE 1 clinical trial results (NCT06143878). ICOTYDE is indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients ≥12 years weighing ≥40 kg. Individual results may vary.
In the ICONIC-ADVANCE 1 trial, 68% of patients achieved clear or almost clear skin at Week 16, and that number rose to 74% by Week 24. Your individual timeline may vary.
In clinical trials through Week 16, the most common side effects were headache (4.1%), nausea (1.2%), cough (1.2%), fungal infections (1.1%), and tiredness (1%). Overall adverse reaction rates were within 1.1 percentage points of placebo, and no new safety signals were identified through Week 52.
ICOTYDE is a 200 mg tablet taken once daily on an empty stomach with water upon waking. Wait at least 30 minutes before eating. If you have difficulty swallowing, the tablet can be placed in at least 120 mL (4 oz) of water, allowed to break apart, and swallowed within 15 minutes.
ICOTYDE is FDA-approved for adults and children aged 12 and older who weigh at least 88 lbs (40 kg) with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
ICOTYDE (icotrokinra) is the first and only targeted oral peptide that blocks the IL-23 receptor, a key part of the immune signaling pathway involved in psoriasis-related inflammation. Unlike injectable biologics, ICOTYDE is taken as a once-daily pill.
Zero waiting rooms, zero co-pays. Get expert care, personalized treatments, and ongoing support, all online for one transparent price.
Licensed dermatology providers who understand acne beyond the surface and guide your treatment from day one.
We handle prior authorizations, pharmacy communication, and refills so you don't have to.
Upload photos directly to your patient dashboard so you and your provider can monitor how your skin is responding to treatment over time.
Message your provider anytime your skin changes, your prescription needs adjusting, or for anything else.
Honeydew membership is eligible for HSA/FSA spending.
Get expert dermatology care from anywhere in the U.S., with no in-person visits required.
Find more answers in our FAQ or Contact us.